Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 8:2022:4764254.
doi: 10.1155/2022/4764254. eCollection 2022.

Effect of Roxadustat on Factors Associated with Renal Fibrosis and Efficacy

Fangfang Zheng  1 , Peng Zhang  1 , Mingzuo Zhao  2 , Jinna Wang  1 , Xiaohong Xu  3 , Chi Zhang  3 , Li Zhang  4
Affiliations

Effect of Roxadustat on Factors Associated with Renal Fibrosis and Efficacy

Fangfang Zheng et al. Comput Math Methods Med. .

Retraction in

Abstract

Objective: We investigated the effect of roxadustat on factors associated with renal fibrosis and efficacy. Methods. Sixty patients meeting the inclusion criteria between January 2021 and October 2021 were equally distributed into observation (roxadustat) group and control (Erythropoietin) group. Then, the expression of serum hypoxia-inducible factor 1-alpha (HIF-1α), transforming growth factor-β (TGF-β1), vascular endothelial growth factor (VEGF), fibronectin (FN), and collagen Ⅳ (C-IV) was compared at different time points (baseline, 2-week follow-up, and 4-week follow-up). The improvement degree of hemoglobin (Hb) and the change level of iron parameters and hepcidin were also compared between the two groups. Results. In the roxadustat group, the expression of HIF-1α at 2 weeks was significantly higher than the baseline and approached the baseline value at 4 weeks. At 4 weeks, TGF-β1 and FN expression was significantly lower than baseline. In addition, the improvement of Hb in the roxadustat group was significantly higher than that in the control group at 4 weeks, and the change of ferritin, transferrin, and hepcidin indexes from baseline was better than in the control group.

Conclusion: After giving roxadustat, it can change the expression of HIF-1α, TGF-β1, and FN. Its efficacy is superior to EPO, which is worthy of clinical application.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Patients characteristics.
Figure 2
Figure 2
The expression level of serum HIF-1α in patients. Note: ∗P < 0.01 vs. baseline.
Figure 3
Figure 3
Changes in expression of TGF-β1, FN, C-IV, and VEGF. Note: ∗P < 0.05 vs. baseline.
Figure 4
Figure 4
Hemoglobin levels. Comparison with baseline values, ∗P < 0.05.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Li J., Wang X. Y., Zhao Z. Z. Investigation of anemia in patients with chronic kidney disease stage 3-5 without dialysis and analysis of influencing factors. Henan Medical Research . 2016;25:629–630.
    1. Batchelor E. K., Kapitsinou P., Pergola P. E., Kovesdy C. P., Jalal D. I. Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment. Journal of the American Society of Nephrology . 2020;31(3):456–468. doi: 10.1681/ASN.2019020213. - DOI - PMC - PubMed
    1. Eckardt K. U., Agarwal R., Aswad A., et al. Safety and efficacy of Vadadustat for anemia in patients undergoing dialysis. The New England Journal of Medicine . 2021;384(17):1601–1612. doi: 10.1056/NEJMoa2025956. - DOI - PubMed
    1. Charles C., Ferris A. H. Chronic kidney disease. Primary Care . 2020;47(4):585–595. doi: 10.1016/j.pop.2020.08.001. - DOI - PubMed
    1. Saglimbene V. M., Palmer S. C., Ruospo M., Natale P., Craig J. C., Strippoli G. F. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews . 2017;8(8, article Cd009904) doi: 10.1002/14651858.CD009904.pub2. - DOI - PMC - PubMed

Publication types